Shining a light on metabolic vulnerabilities in non-small cell lung cancer.

Metabolic reprogramming is a hallmark of cancer which contributes to essential

processes required for cell survival, growth, and proliferation. Non-small cell lung cancer

(NSCLC) is the most common type of lung cancer and its genomic classification has given rise

to the design of therapies targeting tumors harboring specific gene alterations that cause

aberrant signaling. Lung tumors are characterized with having high glucose and lactate use,

and high heterogeneity in their metabolic pathways. Here we review how NSCLC cells with

distinct mutations reprogram their metabolic pathways and highlight the potential metabolic

vulnerabilities that might lead to the development of novel therapeutic strategies.